Pfizer, Flynn Appeal £89M Fines Over UK Epilepsy Drug Prices
Pfizer and Flynn Pharma have appealed a decision by the U.K. Competition and Markets Authority to fine the companies a collective £89.4 million ($111.47 million) for charging the National Health Service...To view the full article, register now.
Already a subscriber? Click here to view full article